NCT01381744View on ClinicalTrials.gov

Dose Escalation Trial of a Plague Vaccine, Flagellin/F1/V, in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Plague
Interventions
BIOLOGICAL

Flagellin/F1/V

Flagellin/F1/V recombinant fusion protein vaccine administered by the intramuscular route on Days 0 and 28 at a dose of 1, 3, 6, or 10 micrograms (mcg). It is a clear, colorless solution.

OTHER

Placebo

Phosphate buffered saline (PBS) used as diluent and placebo.

Trial Locations (1)

63104-1015

Saint Louis University - Center for Vaccine Development, St Louis

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01381744 - Dose Escalation Trial of a Plague Vaccine, Flagellin/F1/V, in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter